Arjun Goyal Buys 417,646 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Director Arjun Goyal acquired 417,646 shares of the business’s stock in a transaction dated Friday, May 16th. The shares were bought at an average price of $12.73 per share, for a total transaction of $5,316,633.58. Following the completion of the acquisition, the director now owns 462,585 shares in the company, valued at approximately $5,888,707.05. This trade represents a 929.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Arjun Goyal also recently made the following trade(s):

• On Thursday, May 15th, Arjun Goyal bought 44,939 shares of Centessa Pharmaceuticals stock. The shares were acquired at an average cost of $12.24 per share, with a total value of $550,053.36.

Centessa Pharmaceuticals Trading Up 7.7%

NASDAQ:CNTA opened at $13.20 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a market cap of $1.76 billion, a PE ratio of -8.63 and a beta of 1.53. The stock’s 50-day moving average is $13.31 and its two-hundred day moving average is $15.54. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd increased its position in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth about $47,000. Barclays PLC increased its position in Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Centessa Pharmaceuticals in the 1st quarter worth approximately $147,000. 82.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on CNTA. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price target for the company. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price target for the company. Morgan Stanley restated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Finally, Chardan Capital began coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set a “buy” rating and a $30.00 price target on the stock. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.